Louis Flamand

Title: Louis Flamand: Innovator in Viral Treatment

Introduction

Louis Flamand is a notable inventor based in California, recognized for his contributions to the field of viral treatment. He has developed innovative methods aimed at combating influenza, showcasing his expertise in biotechnology and therapeutic applications.

Latest Patents

Flamand holds a patent for the "Recombinant human CC10 protein for treatment of influenza." This patent details methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, to reduce virus titers in the tissues of patients, particularly influenza titers in lung tissues. The patent outlines how rhCC10 may be utilized as a therapeutic agent in the treatment, cure, or prevention of viral infections, with a specific focus on influenza. It provides critical dosage ranges and administration routes, including intravenous and intranasal methods, to effectively treat or prevent influenza infections. Additionally, the patent includes compositions that are useful in administering rhCC10 to humans.

Career Highlights

Flamand is associated with Therabron Therapeutics, Inc., where he continues to advance his research and development efforts. His work is pivotal in the ongoing fight against viral infections, particularly in enhancing treatment options for influenza.

Collaborations

Flamand collaborates with esteemed colleagues such as Aprile L Pilon and Pierre Borgeat, contributing to a dynamic research environment focused on innovative therapeutic solutions.

Conclusion

Louis Flamand's work exemplifies the intersection of innovation and healthcare, particularly in the realm of viral treatment. His contributions are significant in the ongoing efforts to improve therapeutic options for influenza and other viral infections.